Moderna reports prelim 2022 COVID sales $18.4B; reiterates 2023 $5B min; RSV study accrues cases

Moderna, Inc.

Prelim 2022 COVID vaccine sales ~$18.4B; R&D ~$3.3B; cash & investments >$18B.
2023 min COVID sales reiterated at ~$5B; R&D budget rises to ~$4.5B.
RSV vaccine (mRNA-1345) Phase 3 in older adults accrued enough cases for first interim efficacy analysis.
Personalized cancer vaccine mRNA-4157 + Keytruda reduced recurrence risk by 44% in melanoma; Phase 3 to start 2023.
Repurchased 23M shares for $3.3B in 2022; $2.8B remaining; acquired OriCiro Genomics.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moderna, Inc. reported the fiscal year ended December 31, 2022 results: revenue approximately $18.4 billion.

Period: the fiscal year ended December 31, 2022
Revenue: approximately $18.4 billion
Result: preliminary results

Exact text from the filing

COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moderna, Inc. reported 2023 results: revenue approximately $5.0 billion. Guidance reaffirmed.

Period: 2023
Revenue: approximately $5.0 billion
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Reiterating 2023 expected minimum COVID-19 vaccines sales of approximately $5.0 billion from confirmed Advance Purchase Agreements and 2022 contract deferrals

View on SEC.gov

Browse all earnings releases →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.